Hitting a pothole on the road in just the wrong way might create a bulge on the tire, a weakened spot that will almost certainly lead to an eventual flat tire. But what if that tire could immediately begin reknitting its rubber, reinforcing the bulge and preventing it from bursting?
Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumours, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.
Years of suffering and billions of euro in global health care costs, arising from osteoporosisrelated bone fractures, could be eliminated using big data to target vulnerable patients, according to researchers at Lero, the Science Foundation Ireland Research Centre for Software.
https://clinlabint.com/wp-content/uploads/sites/2/2021/03/13_NEWS_IMPROVED.jpg5306953wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2021-03-29 23:30:582021-03-30 08:50:22Improved use of databases could save billions of euro in health care costs
A new study from Washington University School of Medicine in St. Louis demonstrates that a liquid biopsy examining blood or urine can help gauge the effectiveness of therapy for colorectal cancer that has just begun to spread beyond the original tumour. Such a biopsy can detect lingering disease and could serve as a guide for […]
https://clinlabint.com/wp-content/uploads/sites/2/2021/03/14_NEWS_LIQUID.jpg4706943wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2021-03-29 23:27:482021-03-30 08:49:59Liquid biopsy for colorectal cancer could guide therapy for tumours
Variants of nine genes increase the risk of developing Addison’s disease, a rare disease in which the immune system attacks the adrenal glands. That is according to the largest genetic study to date on patients with Addison’s disease. The findings help increase knowledge about what causes the disease. The study was conducted by researchers at […]
A study has now been presented that boosts the evidence for using AI solutions in skin cancer diagnostics. With an algorithm they devised themselves, scientists at the University of Gothenburg show the capacity of technology to perform at the same level as dermatologists in assessing the severity of skin melanoma.
https://clinlabint.com/wp-content/uploads/sites/2/2021/03/16_NEWS_DERMATOLOGISTS.jpg43310003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2021-03-29 23:22:582021-03-30 08:49:35Algorithm that performs as accurately as dermatologists
Biomarkers play a central role in the diagnosis of disease and assessment of its course. Among the markers now in use are genes, proteins, hormones, lipids and other classes of molecules. Biomarkers can be found in the blood, in cerebrospinal fluid, urine and various types of tissues, but most of them have one thing in […]
https://clinlabint.com/wp-content/uploads/sites/2/2021/03/17_NEWS_SMARTPHONE.jpg4587263wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2021-03-29 23:20:492021-03-30 08:49:22Detecting single molecules and diagnosing diseases with a smartphone
Children treated for cancer with approaches such as chemotherapy can develop therapyrelated myeloid neoplasms (a second type of cancer) with a dismal prognosis. Scientists at St. Jude Children’s Research Hospital have characterized the genomic abnormalities of 84 such myeloid neoplasms, with potential implications for early interventions to stop the disease. A paper detailing the work […]
https://clinlabint.com/wp-content/uploads/sites/2/2021/03/18_NEWS_MYELOID.jpg39710003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2021-03-29 22:38:282021-03-30 08:49:09Study reveals mutations that drive therapy-related myeloid neoplasms in children
Arctoris, an Oxford-based technology company operating a fully automated drug discovery platform, has – on the occasion of its 5th anniversary – unveiled its new and expanded, next-generation robotic platform, Ulysses.
Arctoris was founded in 2016 as the world’s first fully automated drug discovery platform. Through end-to-end automation, the company’s unique technology platform rapidly delivers reliable, reproducible, and fully auditable datasets enabling better decision-making early in the drug discovery process.
Commenting on the anniversary, the company’s CEO Dr Martin-Immanuel Bittner said: “The drug discovery ecosystem is evolving rapidly, and the key to success is having access to the right data at the right time, to progress the right projects towards the clinic. Arctoris plays an important role in enabling true data-driven drug discovery globally, by generating the data that powers decisions in biotech and pharma companies on three continents.”
Tom Fleming, COO of Arctoris, added:“Drug discovery is undergoing a rapid digital metamorphosis, and Ulysses plays a central catalytic role in that transformation. This success is the result of our amazing team’s dedication and hard work over these past five years, combined with guidance from experienced and insightful advisors and board members. We are looking forward to the next five years, which will see even greater change and accelerated growth, toward a future where treatments and cures can be generated at a fraction of the time and cost, and we are privileged to play our role in building that future.”
Having strengthened its team over the past few years with several high-profile hires and Advisory Board appointments, the company has recently announced partnerships with Insilico Medicine and Syntekabio, while further expanding its operations globally.
The Chairman of the Board, Dr Vishal Gulati, echoed the founders’ enthusiasm: “Five years ago, the founders set out with the idea to make it possible for any scientist in the world to run a biotech company with a laptop and a credit card – and thanks to Arctoris, this is now entirely possible, harnessing the power of automation for drug discovery. As Chairman of the Board of Arctoris, I am incredibly proud of where the Company stands today, and I am excited about what lies ahead, on our path to redesigning drug discovery from the ground up.”
https://clinlabint.com/wp-content/uploads/sites/2/2021/03/Acrtoris_Ulysses.jpg600900panglobalhttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.pngpanglobal2021-03-26 08:42:072021-03-26 08:42:07Arctoris celebrates 5th anniversary, launches Ulysses robotic platform for drug discovery
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.